ACROMEGALY
Clinical trials for ACROMEGALY explained in plain language.
Never miss a new study
Get alerted when new ACROMEGALY trials appear
Sign up with your email to follow new studies for ACROMEGALY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Spine fracture showdown: new drug may outperform standard in acromegaly
Disease control Recruiting nowThis study looks at two medications for acromegaly, a condition causing too much growth hormone. The goal is to see which drug better prevents spine fractures over one year. About 120 adults whose acromegaly is not controlled by first-line treatments will take either Pasireotide …
Matched conditions: ACROMEGALY
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for acromegaly: experimental drug aims to tame hormone levels
Disease control Recruiting nowThis study tests whether adding a new drug, ALXN2420, to standard acromegaly treatment can better lower a key hormone (IGF-1) linked to the disease. About 60 adults with acromegaly who are already on a stable monthly injection will receive either ALXN2420 or a placebo for 15 week…
Matched conditions: ACROMEGALY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New 12-Week injection could simplify acromegaly treatment
Disease control Recruiting nowThis study tests a new long-acting drug called Debio 4126 for people with acromegaly, a condition where the body makes too much growth hormone. The drug is given as an injection every 12 weeks and aims to keep hormone levels normal. About 119 adults who are already on similar med…
Matched conditions: ACROMEGALY
Phase: PHASE3 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
Healthy men needed to test safety of experimental acromegaly drug
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called MAR002 in 45 healthy men aged 18 to 40. Participants receive either the drug or a placebo injection, and researchers monitor for side effects and how the drug moves through the body. The study does not aim to treat any …
Matched conditions: ACROMEGALY
Phase: PHASE1 • Sponsor: Marea Therapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 04:11 UTC